Porownywarka
Orforglipron vs Semaglutide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Orforglipron | Semaglutide |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | LY3502970, OWL833 | Ozempic, Wegovy, Rybelsus |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA approved in 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
| FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.
|
| Czego oczekiwac | Oral weight-loss option, diabetes, convenience | Weight loss, appetite control, blood sugar management |
| Jak dziala | Orforglipron is described as a small-molecule GLP-1 receptor agonist. The supplied mechanism text connects GLP-1 receptor activation with appetite reduction, slower gastric emptying, and glucose-dependent insulin release. The same evidence emphasizes oral stability as the chemistry-based distinction from peptide GLP-1 agents, not a different receptor target. | According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration. |
| Typowe dawkowanie | Limited community data available · See research protocols · Oral tablet daily | 1-2.4 mg weekly (after titration) · Once weekly |
| Dawkowanie z badań | 12-45mg once daily · Long-term use expected · Oral tablet daily | 0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus) |
| Typowy czas trwania | Long-term use expected | Long-term / chronic use |
| Podanie | Oral tablet daily | Subcutaneous injection weekly, or oral (Rybelsus) |
| Timing | - With or without food | Morning, same day each week With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+3 więcej
|
+10 więcej
|
| Podsumowanie researchu | The source summarizes a late-stage clinical program. It reports ATTAIN-1 as a 72-week obesity trial in which three dose groups outperformed placebo for weight loss, with full results said to appear in the New England Journal of Medicine. ATTAIN-2 is described in adults with obesity and type 2 diabetes, with weight loss and changes in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. For diabetes, ACHIEVE-1 is characterized as a Phase 3 success for an oral small-molecule GLP-1 agent, and ACHIEVE-3 is reported as a head-to-head comparison where orforglipron exceeded oral semaglutide on A1C and weight. The same source frames the main advance as oral delivery rather than a new GLP-1 mechanism. | The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.